Roth Capital initiated coverage on Creative Medical Tech with a new price target
$CELZ
Finance: Consumer Services
Finance
Roth Capital initiated coverage of Creative Medical Tech with a rating of Buy and set a new price target of $10.00
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 2/25/2022 | $10.00 | Buy | Roth Capital |
PHOENIX, March 20, 2025 (GLOBE NEWSWIRE) -- Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ) (the "Company"), a clinical-stage biotechnology company specializing in regenerative medicine, today announced that the U.S. Food and Drug Administration (FDA) has cleared an expanded dose escalation for its ongoing Phase 1/2 trial of StemSpine® using AlloStem™ (CELZ-201-DDT), the Company's proprietary allogeneic (donor) cell therapy for chronic lower back pain caused by degenerative disc disease (DDD). This regulatory milestone follows compelling interim blinded data demonstrating statistically significant pain reduction and improved mobility among trial participants. The first-of-its-kin
PHOENIX, March 06, 2025 (GLOBE NEWSWIRE) -- Creative Medical Technology Holdings, Inc., (NASDAQ:CELZ) (the "Company"), a leading biotechnology innovator in regenerative medicine, today announced it has entered into agreements with certain holders of its existing warrants for the immediate exercise of certain outstanding warrants to purchase up to an aggregate of 837,104 shares of common stock of the Company originally issued in October 2024 at their current exercise price of $4.42 per share. The shares of common stock issuable upon exercise of the existing warrants are registered pursuant to an effective registration statement on Form S-1 (File No. 333-283091). The aggregate gross proceeds
PHOENIX, Feb. 20, 2025 (GLOBE NEWSWIRE) -- Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ), a leading biotechnology innovator in regenerative medicine, enthusiastically supports President Donald J. Trump's executive order expanding access to in vitro fertilization (IVF). This initiative directly aligns with the company's vision to transform reproductive health through its groundbreaking OvaStem® program, which has demonstrated an 85% improvement in hormonal function and a 70% success rate in delivering healthy babies using a patient's own eggs—all with no safety concerns at up to five years post-treatment. Patients with Primary Ovarian Insufficiency (POI) typically face only a
Roth Capital initiated coverage of Creative Medical Tech with a rating of Buy and set a new price target of $10.00
10-Q - CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (0001187953) (Filer)
8-K - CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (0001187953) (Filer)
10-K/A - CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (0001187953) (Filer)
4 - CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (0001187953) (Issuer)
4 - CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (0001187953) (Issuer)
4 - CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (0001187953) (Issuer)
PHOENIX, Ariz. , March 2, 2022 /PRNewswire/ -- Creative Medical Technology Holdings, Inc. ("Creative Medical Technology" or the "Company") (NASDAQ:CELZ), a leading commercial stage biotechnology company focused on a regenerative approach to immunotherapy, urology, neurology, and orthopedics, today announced the appointment of Sahil Nock as the Company's Chief Commercial Officer, effective February 28, 2022. Mr. Nock brings to Creative Medical Technology more than 15 years of healthcare leadership experience in sales, marketing, and business development. He most recently served
SC 13G/A - CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (0001187953) (Subject)
SC 13G - CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (0001187953) (Subject)
SC 13G/A - CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (0001187953) (Subject)